ERAS
Erasca, Inc.
$17.63
+0.55
(+3.22%)
Mkt Cap
6.12B
Volume
2,445,434
52W Range
1.33-24.28
Sector
Healthcare
Beta
0.65
EPS (TTM)
-0.95 USD
P/E Ratio
-8.45
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (124.55M) | (161.65M) | (125.04M) | (242.81M) | (122.76M) | (101.66M) | (12.04M) |
| EPS | -0.44 | -0.69 | -0.83 | -1.99 | -1.03 | -0.85 | -0.10 |
| Free Cash Flow | (95.58M) | (131.98M) | (102.99M) | (119.81M) | (98.48M) | (71.38M) | (10.97M) |
| FCF / Share | -0.34 | -0.56 | -0.69 | -0.98 | -0.83 | -0.60 | -0.09 |
| Operating CF | (95.45M) | (109.42M) | (101.22M) | (103.26M) | (79.60M) | (32.69M) | (10.38M) |
| Total Assets | 396.15M | 502.53M | 395.30M | 514.91M | 501.42M | 124.83M | 55.51M |
| Total Debt | 47.14M | 51.89M | 55.86M | 55.10M | 18.79M | 2.99M | 3.69M |
| Cash & Equiv | 73.81M | 67.74M | 93.08M | 284.22M | 360.49M | 65.38M | 29.58M |
| Book Value | 325.17M | 423.50M | 316.69M | 411.85M | 456.53M | 107.42M | (13.60M) |
| Return on Equity | -0.38 | -0.38 | -0.39 | -0.59 | -0.27 | -0.95 | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (44.08M) | (183.44M) | (29.09M) | (30.61M) | (33.88M) | (30.97M) | (32.23M) | (31.20M) | (63.20M) | (35.02M) | (29.70M) | (30.36M) |
| EPS | -0.14 | -0.60 | -0.10 | -0.11 | -0.12 | -0.11 | -0.11 | -0.11 | -0.29 | -0.23 | -0.20 | -0.20 |
| Free Cash Flow | (27.28M) | (27.42M) | (21.72M) | (21.66M) | (20.56M) | (31.64M) | (24.56M) | (22.42M) | (29.20M) | (33.29M) | (24.87M) | (24.36M) |
| FCF / Share | -0.09 | -0.09 | -0.08 | -0.08 | -0.07 | -0.11 | -0.09 | -0.08 | -0.13 | -0.22 | -0.16 | -0.16 |
| Operating CF | (27.27M) | (27.38M) | (21.71M) | (21.66M) | (20.53M) | (31.55M) | (24.56M) | (22.42M) | (29.18M) | (33.25M) | (24.79M) | (24.12M) |
| Total Assets | 435.05M | 461.23M | 396.15M | 420.40M | 445.39M | 471.24M | 502.53M | 528.90M | 525.74M | 370.02M | 395.30M | 419.41M |
| Total Debt | 44.71M | 45.95M | 47.14M | 48.29M | 49.42M | 50.81M | 51.89M | 52.94M | 53.97M | 65.97M | 55.86M | 56.76M |
| Cash & Equiv | 42.54M | 47.26M | 73.81M | 70.23M | 66.14M | 70.48M | 67.74M | 68.89M | 172.80M | 76.73M | 93.08M | 112.86M |
| Book Value | 361.87M | 393.53M | 325.17M | 347.89M | 372.26M | 399.50M | 423.50M | 450.04M | 451.09M | 288.41M | 316.69M | 338.98M |
| Return on Equity | -0.12 | -0.47 | -0.09 | -0.09 | -0.09 | -0.08 | -0.08 | -0.07 | -0.14 | -0.12 | -0.09 | -0.09 |
ERAS News
ERASCA, INC. (ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
81,900 Shares in Erasca, Inc. $ERAS Acquired by Handelsbanken Fonder AB
Bank of America Corp DE Raises Position in Erasca, Inc. $ERAS
Erasca Reports Second Quarter 2026 Business Updates and Financial Results
ERASCA DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action - ERAS
Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with SBS Law
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP By Application Deadline
Erasca, Inc. Investor Alert: Contact SBS by August 10, 2026 for Opportunity to Lead Securities Fraud Lawsuit